JP2023508182A5 - - Google Patents
Info
- Publication number
- JP2023508182A5 JP2023508182A5 JP2022539212A JP2022539212A JP2023508182A5 JP 2023508182 A5 JP2023508182 A5 JP 2023508182A5 JP 2022539212 A JP2022539212 A JP 2022539212A JP 2022539212 A JP2022539212 A JP 2022539212A JP 2023508182 A5 JP2023508182 A5 JP 2023508182A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- triazolo
- triazine
- furan
- diamine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911364028.2 | 2019-12-26 | ||
| CN201911364028 | 2019-12-26 | ||
| PCT/CN2020/139690 WO2021129843A1 (zh) | 2019-12-26 | 2020-12-25 | 三唑并三嗪衍生物在治疗疾病中的用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023508182A JP2023508182A (ja) | 2023-03-01 |
| JP2023508182A5 true JP2023508182A5 (enExample) | 2024-01-04 |
Family
ID=76573699
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022539212A Pending JP2023508182A (ja) | 2019-12-26 | 2020-12-25 | トリアゾロトリアジン誘導体の疾患治療への応用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20230048888A1 (enExample) |
| EP (1) | EP4083044A4 (enExample) |
| JP (1) | JP2023508182A (enExample) |
| CN (1) | CN114901665B (enExample) |
| WO (1) | WO2021129843A1 (enExample) |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5356894A (en) * | 1990-05-29 | 1994-10-18 | Rodney Peter W | Morpholinyl substituted [1,2,4]-triazolo[1,5-a]triazine as antagonist |
| EP0459702A1 (en) * | 1990-05-29 | 1991-12-04 | Zeneca Limited | Azole Derivatives |
| GB9111131D0 (en) * | 1991-05-23 | 1991-07-17 | Ici Plc | Heterocyclic compounds |
| GB9125002D0 (en) * | 1991-11-25 | 1992-01-22 | Ici Plc | Azole derivatives |
| CA2148502A1 (en) * | 1993-09-06 | 1995-03-16 | Fumio Suzuki | Antidepressants |
| JP4228048B2 (ja) | 2000-10-09 | 2009-02-25 | ピーオーダブリューエムアールアイ リミテッド | 神経変性障害の検出方法 |
| DE60231386D1 (de) * | 2001-04-09 | 2009-04-16 | Neurosearch As | Adenosin-a2a-rezeptor-antagonisten in kombination mit verbindungen mit neurotrophischer aktivität bei der behandlung von morbus parkinson |
| IL161573A0 (en) * | 2001-11-30 | 2004-09-27 | Schering Corp | [1,2,4]-TRIAZOLE BICYCLIC ADENOSINE A2a RECEPTOR ANTAGONISTS |
| WO2004092173A2 (en) * | 2003-04-09 | 2004-10-28 | Biogen Idec Ma Inc. | A2a adenosine receptor antagonists |
| EP3328418A1 (en) * | 2015-07-29 | 2018-06-06 | Novartis AG | Combination therapies comprising antibody molecules to pd-1 |
| WO2018013951A1 (en) * | 2016-07-15 | 2018-01-18 | Northwestern University | Targeting adenosine a2a receptors for the treatment of levodopa-induced dyskinesias |
| TWI801372B (zh) * | 2017-03-30 | 2023-05-11 | 比利時商艾特歐斯比利時有限公司 | 作為a2a抑制劑的硫胺甲酸酯衍生物以及用於癌症治療的方法 |
| KR102633145B1 (ko) * | 2018-06-26 | 2024-02-05 | 쩌지앙 빔그린 파머슈티컬스, 엘티디 | A2a 수용체 길항제로서의 트리아졸로 트리아진 유도체 |
| JP7197206B2 (ja) * | 2018-06-26 | 2022-12-27 | チョーチヤン ビムグリーン ファーマシューティカルズ、リミテッド | Ａ２ａ受容体拮抗薬として用いられるトリアゾロトリアジン誘導体 |
-
2020
- 2020-12-25 JP JP2022539212A patent/JP2023508182A/ja active Pending
- 2020-12-25 CN CN202080089936.XA patent/CN114901665B/zh active Active
- 2020-12-25 EP EP20908293.2A patent/EP4083044A4/en not_active Withdrawn
- 2020-12-25 US US17/789,126 patent/US20230048888A1/en active Pending
- 2020-12-25 WO PCT/CN2020/139690 patent/WO2021129843A1/zh not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017528498A5 (enExample) | ||
| TWI694076B (zh) | 三唑并嘧啶化合物及其用途 | |
| AU2014372166B2 (en) | Pharmaceutical combinations | |
| JP2021011495A5 (enExample) | ||
| JP2019529484A5 (enExample) | ||
| JP2022505835A5 (enExample) | ||
| JP2019517487A5 (enExample) | ||
| RU2017121044A (ru) | Производные амидотиадиазола в качестве ингибиторов надфн-оксидазы | |
| JP2022500496A5 (enExample) | ||
| JP2019501197A5 (ja) | 腫瘍を処置するための抗ｈｅｒ２組み合わせ | |
| JP2018520195A5 (enExample) | ||
| RU2013143028A (ru) | Тиазолилфенилбензолсульфонамидопроизводные в качестве ингибиторов киназ | |
| US20080207572A1 (en) | Use of Dual C-Kit/Fgfr3 Inhibitors for Treating Multiple Myeloma | |
| JP2018511631A5 (enExample) | ||
| JP2012507566A5 (enExample) | ||
| RU2010150786A (ru) | Пирролопиридины как ингибиторы киназы | |
| RU2018127728A (ru) | Слитые трициклические гетероциклические соединения в качестве ингибиторов интегразы вич | |
| CA2659425A1 (en) | Triazole compounds that modulate hsp90 activity | |
| JP2016522246A5 (enExample) | ||
| US11401278B2 (en) | Macrocyclic indole derivatives | |
| AU2006272652B2 (en) | 1,2,3-triazoles inhibitors of tubulin polymerization for the treatment of proliferative disorders | |
| EA034872B1 (ru) | Комбинация ингибитора mek кобиметиниба и ингибитора erk (s)-1-(1-(4-хлор-3-фторфенил)-2-гидроксиэтил)-4-(2-((1-метил-1h-пиразол-5-ил)амино)пиримидин-4-ил)пиридин-2(1h)-она для применения в лечении раковых заболеваний | |
| JP2020527173A5 (enExample) | ||
| JP2019501196A5 (ja) | 腫瘍を処置するための抗ｃｄ２０組み合わせ | |
| JP2016525104A5 (enExample) |